MRK Merck & Co Inc

  1. Stocks
  2. Healthcare
  3. NYSE: MRK

Price (delayed)

$147.68

Market cap

$364.07B

P/E Ratio

147.68

Dividend/share

$3.4

EPS

$1

Enterprise value

$408.29B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 49

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives ...

Highlights
The revenue has grown by 4.9% YoY
MRK's quick ratio is down by 26% year-on-year but it is up by 10% since the previous quarter
Merck's equity has decreased by 13% YoY but it has increased by 7% from the previous quarter
The P/E is 100% higher than the last 4 quarters average of 73.7 and 88% higher than the 5-year quarterly average of 78.3
The EPS has plunged by 87% YoY and by 21% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.merck.com
Peers: PFE JNJ LLY BMY

Key stats

What are the main financial stats of MRK

MRK stock price

How has the Merck stock price performed over time
Intraday
0.34%
1 week
0.5%
1 month
1.53%
1 year
61.49%
YTD
40.3%
QTD
1.63%

Financial performance

How have Merck's revenue and profit performed over time
Revenue
$67.38B
Gross profit
$48.35B
Operating income
$5.46B
Net income
$2.45B
Gross margin
71.8%
Net margin
3.6%
MRK's net margin has dropped by 88% year-on-year and by 25% since the previous quarter
The net income has dropped by 87% year-on-year and by 23% since the previous quarter
Merck's operating margin has shrunk by 76% YoY and by 16% QoQ
Merck's operating income has plunged by 75% YoY and by 14% from the previous quarter

Price vs fundamentals

How does MRK's price correlate with its fundamentals

Growth

What is Merck's growth rate over time

Valuation

What is Merck stock price valuation
MRK P/E details
P/E
147.68
P/B
8.12
P/S
5.41
EV/EBIT
60.69
EV/EBITDA
29.02
EV/Sales
6.06
The P/E is 100% higher than the last 4 quarters average of 73.7 and 88% higher than the 5-year quarterly average of 78.3
The EPS has plunged by 87% YoY and by 21% from the previous quarter
The price to book (P/B) is 35% higher than the 5-year quarterly average of 6.0 and 19% higher than the last 4 quarters average of 6.8
Merck's equity has decreased by 13% YoY but it has increased by 7% from the previous quarter
MRK's P/S is 25% above its 5-year quarterly average of 4.3 and 15% above its last 4 quarters average of 4.7
The revenue has grown by 4.9% YoY

Efficiency

How efficient is Merck business performance
The company's return on assets has shrunk by 88% YoY and by 21% QoQ
Merck's ROE has plunged by 86% YoY and by 20% from the previous quarter
The ROIC has shrunk by 76% YoY and by 15% QoQ
The ROS has plunged by 72% YoY and by 14% from the previous quarter

Dividends

What is MRK's dividend history
Dividend details
DPS
$3.4
Dividend yield
2.3%
Payout ratio
340%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Merck financials performed over time
The total assets is 51% more than the total liabilities
MRK's quick ratio is down by 26% year-on-year but it is up by 10% since the previous quarter
The current ratio has contracted by 19% YoY but it has grown by 2.3% from the previous quarter
MRK's debt is 20% greater than its equity
The debt to equity has soared by 50% YoY but it has contracted by 7% from the previous quarter
MRK's debt is up by 30% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.